A new article in the February 2015 of the Journal of Urology may actually tell us as much (or more) about the difficulties of relying on data from large, retrospective analyses of single institution data as it does about the actual issue references in the headline above. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, inhibitor, PDE5, phosphdiesterase 5, recurrence, risk, surgery | 4 Comments »
According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: avanafil, ED, erctile dysfunction, inhibitor, PDE5 | Leave a comment »
Recent publications reported on today include:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, criteria, Epstein, fusion, gene, inhibitors, insignificant, news, PDE5, prostate, update | 4 Comments »
